Table 1 Patients’ characteristics at the start of pembrolizumab treatment (n = 150).
Parameter | Value |
|---|---|
Age, years, median (IQR) | 71 (66–76) |
Sex, no. (%) | |
Male | 111 (74) |
Female | 39 (26) |
ECOG PS, no. (%) | |
0 | 84 (56) |
1 | 48 (32) |
2 | 14 (9) |
3 | 4 (3) |
Primary site, no. (%): | |
Bladder | 66 (44) |
Upper tract | 67 (45) |
Both | 17 (11) |
Resection of primary site, no. (%) | 109 (73) |
Lymph node metastasis, no. (%) | 93 (62) |
Visceral metastasis, no. (%) | 106 (71) |
Lung metastasis, no. (%) | 59 (39) |
Bone metastasis, no. (%) | 30 (20) |
Liver metastasis, no. (%) | 27 (18) |
No. of prior regimens, no. (%) | |
1 | 117 (78) |
2 | 25 (17) |
3 | 8 (5) |
Pretreatment laboratory parameters, median (IQR) | |
AGR | 1.20 (1.00–1.46) |
NLR | 3.34 (2.20–5.36) |
Hemoglobin (g/dL) | 10.9 (9.4–12.2) |
eGFR (mL/min/1.73 m2) | 48.0 (38.1–61.9) |
C-reactive protein (mg/dL) | 0.69 (0.15–2.50) |
